Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Core Viewpoint - Johnson Fistel, PLLP is investigating potential shareholder derivative claims against Sarepta Therapeutics, Inc. regarding alleged breaches of fiduciary duties by certain officers and directors, following a securities class action related to Sarepta's stock performance during the Class Period from June 22, 2023 to June 24, 2025 [1][4]. Group 1 - The investigation is prompted by allegations that Sarepta and its senior executives made materially false and misleading statements and failed to disclose adverse facts, particularly concerning the safety profile of their gene therapy product, ELEVIDYS [4][5]. - Significant stock price declines were noted, including a 27% drop following the announcement of a patient death on March 18, 2025, and a further decline of over 40% after a second patient death was reported on June 15, 2025 [4]. - The FDA issued a safety communication regarding the deaths, which further impacted Sarepta's share price [4]. Group 2 - The investigation focuses on whether Sarepta's board and senior management allowed misconduct, failed to implement adequate safety oversight, and exposed the company to regulatory, financial, and reputational risks [5]. - Current shareholders who held shares continuously before June 22, 2023, may have the standing to pursue derivative claims on behalf of the company [2].